
16:34 EST Palatin (PTN) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PTN | Palatin Technologies | 4.58 | -18.24 | -79.93% |
| Name | Price | % Change | |
|---|---|---|---|
| $4.58 | -79.93% |

16:34 EST Palatin (PTN) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on

Palatin Technologies, Inc. (($PTN)) has held its Q1 earnings call. Read on for the main highlights of the call. The call struck an optimistic tone as Palatin Technologies highlighted progress

Reports Q1 revenue $361,802 vs. $8.85M last year. “MC4R agonism is now a clinically and commercially validated therapeutic approach for rare neuroendocrine obesity disorders, and we believe the next generation

Palatin (PTN) announced the presentation of new preclinical data highlighting the company’s proprietary MC4R-selective peptide agonist programs at ObesityWeek 2026, November 14-17 in Washington, D.C. The findings demonstrate “potent and

Palatin (PTN) announced the presentation of new preclinical data highlighting the company’s proprietary MC4R-selective peptide agonist programs at ObesityWeek 2026, November 14-17 in Washington, D.C. The findings demonstrate “potent and

WSW, NY, November 11th, 2026, FinanceWire A reported offer for the established MC4R franchise and fresh funding for Lilly-backed Superluminal point to growing interest in the brain’s hunger pathway. Palatin

H.C. Wainwright re-initiated coverage of Palatin (PTN) with a Buy rating and $12 price target The company has expertise in the melanocortin arena, including the approved Vyleesi, and several consummated

WSW, NY, October 21st, 2026, FinanceWire Recent acquisitions and licensing deals reveal what drugmakers want next: different biology, better dosing and treatments that can complement existing medicines. Palatin is developing

Palatin Technologies, Inc. (($PTN)) has held its Q4 earnings call. Read on for the main highlights of the call. Palatin Technologies’ latest earnings call balanced scientific optimism with stark financial

WSW, NY, September 15th, 2026, FinanceWire The GLP-1 boom created one of the largest new drug markets in a generation. But as investment moves deeper into obesity, the category is
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 17, 2027TBA | $8.78M | $-1.17 | $639.00K | 0.04 | -0.40 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.